Anti-Obesity Drugs Market size is set to grow by USD 18.33 billion from 2024-2028, Growing obese population boost the market, Technavio

NEW YORK, June 7, 2024 /PRNewswire/ -- The global anti-obesity drugs market size is estimated to grow by USD 18.33 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  14.44%  during the forecast period. Growing obese population is driving market growth, with a trend towards research on drugs that target both obesity and type 2 diabetes mellitus. However, availability of anti-obesity devices  poses a challenge. Key market players include Alvogen Iceland ehf, Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., Empros Pharma AB, ERX Pharmaceuticals Inc., Gelesis Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., LG Chem Ltd., Novo Nordisk AS, Rhythm Pharmaceuticals Inc., SCOHIA PHARMA Inc., VIVUS LLC, and Zydus Lifesciences Ltd..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

Market Driver

The global anti-obesity drugs market is experiencing significant growth due to the increasing prevalence of obesity and type 2 diabetes. These conditions, which are metabolic syndromes, are linked to comorbidities such as hypertension and dyslipidemia, leading to cardiovascular diseases. BMI is a key indicator of both diabetes and insulin resistance. Insulin resistance is a common factor between obesity and type 2 diabetes.

Pharmaceutical companies like AstraZeneca are developing new drugs, such as MEDI0382, which targets both obesity and type 2 diabetes, currently in phase II of development. The demand for anti-obesity drugs is increasing as new treatments offer relief to millions affected by these conditions. 

The Caloric Consumption market is witnessing significant growth due to the increasing prevalence of obesity worldwide. Anti-Obesity Drugs are gaining popularity as an effective solution for weight management. Calories are essential for energy production, but an excess intake can lead to weight gain. Caloric intake can be managed through diet and exercise, but sometimes medication is necessary. Caloric Consumption drugs work by suppressing appetite, increasing metabolism, or blocking the absorption of dietary fat.

The market for these drugs is expanding, with new players entering the market and existing ones introducing new formulations. The market is expected to continue growing, driven by the rising obesity rates and increasing awareness of the health risks associated with obesity. The market for these drugs is competitive, with companies constantly innovating to offer more effective and safer solutions. The market is also being driven by regulatory approvals and reimbursement policies in various countries. The market for Caloric Consumption drugs is a growing business opportunity for companies looking to address the global obesity epidemic. 

Research report provides comprehensive data on impact of trend. For more details- Download a Sample Report

Market Challenges

•         The obesity treatment landscape is shifting towards devices, posing a challenge for the anti-obesity drugs market. FDA-approved devices like gastric bands, electrical stimulation systems, gastric balloons, and gastric emptying systems offer faster results, leading more obese individuals to opt for these treatments over drugs. This trend is expected to decrease the demand for anti-obesity drugs during the forecast period.

•         The anti-obesity drugs market faces several challenges. Drugs like Orlistat, Appetite suppressants, and Diabetes drugs are commonly used. However, the effectiveness of these drugs varies from person to person. Consumers look for long-term solutions and safety concerns. Regulations and ethical considerations also pose challenges.

•         The cost of these drugs is a significant barrier for many potential users. Additionally, the prevalence of obesity continues to rise, increasing the demand for effective and affordable anti-obesity drugs. Companies must innovate and collaborate to address these challenges and meet consumer needs.

For more insights on driver and challenges - Request a sample report!

Segment Overview 

1. Type 
• 1.1 Class III anti-obesity drugs
• 1.2 Class II anti-obesity drugs
• 1.3 Class I anti-obesity drugs
2. Drug Class
• 2.1 Peripherally acting drugs
• 2.2 Centrally acting drugs
3. Geography 
• 3.1 North America
• 3.2 Europe
• 3.3 Asia
• 3.4 Rest of World (ROW)

1.1 Class III anti-obesity drugs-  The Class III anti-obesity drugs segment, which caters to patients with severe obesity, dominates the global market. Manufacturers are investing in research and development for new drugs, driving growth. However, the YOY growth rate is projected to decrease due to the rising prevalence of morbid obesity. This condition often requires bariatric surgery for effective treatment, limiting the role of pharmacotherapy in reducing body mass index.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) - Download a Sample Report

Research Analysis

The Anti-Obesity Drugs Market represents a significant industry sector, addressing the prevalence of obesity and related chronic diseases worldwide. Obesity, characterized by an excess of body fat, is a global endemic affecting children and adolescents, as well as adults. Obesity is linked to various chronic conditions, including insulin resistance, glucose intolerance, hypertension, sleep apnea, diabetes mellitus, and arthritis.

These conditions result from an energy imbalance, where calories consumed exceed calories expended. Anti-obesity drugs aim to address this imbalance by suppressing appetite, reducing fat absorption, or increasing energy consumption. These medications can help manage weight loss in individuals struggling with obesity. However, it is essential to note that these drugs should be used in conjunction with a healthy lifestyle, including a balanced diet, regular physical activity, and stress management.

The market for anti-obesity drugs is driven by the increasing prevalence of obesity and its associated chronic diseases. Smoking and drinking can also contribute to obesity and further complicate health issues. As lifestyle-related illnesses continue to rise, the demand for effective weight loss solutions, including anti-obesity drugs, is expected to grow.

The Anti-Obesity Drugs Market encompasses a range of pharmaceutical solutions designed to manage and reduce excess body weight. These drugs work by suppressing appetite, increasing satiety, and enhancing metabolism. The market is driven by the rising prevalence of obesity and associated health complications, such as diabetes and cardiovascular diseases.

The market also benefits from increasing consumer awareness and acceptance of weight loss treatments. The drugs in this market include those that act on the central nervous system, such as anorectics, and those that target specific hormones, like GLP-1 agonists. The market is expected to grow significantly due to the increasing global obesity epidemic and the development of new, more effective treatments.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Type
• Class III Anti-obesity Drugs
• Class II Anti-obesity Drugs
• Class I Anti-obesity Drugs
• Drug Class
• Peripherally Acting Drugs
• Centrally Acting Drugs
• Geography
• North America
• Europe
• Asia
• Rest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio